Welcome to our dedicated page for Septerna SEC filings (Ticker: SEPN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Septerna, Inc. (Nasdaq: SEPN) SEC filings, offering detailed regulatory disclosures about the company’s operations as a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery. As an issuer with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC or The Nasdaq Global Market, Septerna files current and periodic reports that describe its business, governance and financial condition.
Septerna’s Form 8-K filings frequently cover material events such as quarterly financial results and business highlights, including revenue, research and development expenses, general and administrative expenses, net income or loss, cash and marketable securities, working capital, total assets, total liabilities and stockholders’ equity. Other 8-Ks disclose collaboration agreements, such as the global collaboration and license agreement with Novo Nordisk A/S, leadership and board appointments, executive role changes, investor presentations and annual meeting voting results.
Through its SEC filings, Septerna also reports on matters like director elections, committee assignments, non-employee director compensation, and submission of matters to a vote of stockholders. These documents provide insight into the company’s corporate governance framework, including the composition of its board and committees and the outcomes of shareholder votes.
On Stock Titan, Septerna’s filings are updated in near real time as they are made available on EDGAR. AI-powered summaries help explain the key points of lengthy filings, so readers can quickly understand the implications of new 8-Ks and other reports without reviewing every page. Users can review historical filings to track trends in Septerna’s financials, follow the evolution of its collaborations and governance, and monitor ongoing disclosure about its GPCR-focused pipeline and clinical-stage programs.
Septerna, Inc. received an updated ownership report from Biotechnology Value Fund and affiliated entities on a Schedule 13G/A Amendment No. 2. As of the close of business on December 31, 2025, BVF, BVF2 and Biotechnology Value Trading Fund OS together beneficially owned 1,720,782 shares of Septerna common stock through various funds and a managed account.
This position represents approximately 3.8% of Septerna’s 44,774,192 shares outstanding as of November 4, 2025, as reported by the company. The reporting group certifies that the shares were not acquired and are not held for the purpose of changing or influencing control of Septerna.
Septerna, Inc. reported an insider equity award for Daniel D. Long, its SVP of Drug Discovery. On February 6, 2026, he was granted a stock option to buy 80,000 shares of common stock at an exercise price of $25.41 per share.
According to the vesting schedule, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as he continues to provide service to Septerna.
Septerna, Inc. reported an insider equity award for Daniel D. Long, its SVP of Drug Discovery. On February 6, 2026, he was granted a stock option to buy 80,000 shares of common stock at an exercise price of $25.41 per share.
According to the vesting schedule, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as he continues to provide service to Septerna.
Septerna, Inc. officer Uwe Klein, SVP, Biological Sciences, received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $25.41 per share and were awarded on February 6, 2026.
According to the vesting schedule, 2/48 of the option shares will vest and become exercisable on March 1, 2026, with the remaining shares vesting in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on Klein’s continued service with Septerna.
Septerna, Inc. officer Uwe Klein, SVP, Biological Sciences, received a grant of stock options covering 80,000 shares of common stock. The options have an exercise price of $25.41 per share and were awarded on February 6, 2026.
According to the vesting schedule, 2/48 of the option shares will vest and become exercisable on March 1, 2026, with the remaining shares vesting in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on Klein’s continued service with Septerna.
Septerna, Inc. reported that Chief People Officer Samira Shaikhly received a new stock option grant. On February 6, 2026, she was awarded options to purchase 80,000 shares of Septerna common stock at an exercise price of $25.41 per share, held as direct ownership.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining portion will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on her continued service. The option is scheduled to expire on February 5, 2036.
Septerna, Inc. reported that Chief People Officer Samira Shaikhly received a new stock option grant. On February 6, 2026, she was awarded options to purchase 80,000 shares of Septerna common stock at an exercise price of $25.41 per share, held as direct ownership.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining portion will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on her continued service. The option is scheduled to expire on February 5, 2036.
Septerna, Inc.'s Chief Financial Officer, Gil M. Labrucherie, received a grant of stock options on 125,000 shares of common stock on February 6, 2026, with an exercise price of $25.41 per share and direct ownership.
According to the vesting terms, 2/48 of the option vests and becomes exercisable on March 1, 2026. The remaining shares vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as the executive remains in continuous service with Septerna. The options expire on February 5, 2036.
Septerna, Inc.'s Chief Financial Officer, Gil M. Labrucherie, received a grant of stock options on 125,000 shares of common stock on February 6, 2026, with an exercise price of $25.41 per share and direct ownership.
According to the vesting terms, 2/48 of the option vests and becomes exercisable on March 1, 2026. The remaining shares vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as the executive remains in continuous service with Septerna. The options expire on February 5, 2036.
Septerna’s Chief Medical Officer, Kim Jae B., reported receiving a new stock option award in common stock. On February 6, 2026, a stock option covering 125,000 shares was granted with an exercise price of $25.41 per share.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on Kim’s continuous service with Septerna. After this grant, Kim holds 125,000 stock options directly.
Septerna’s Chief Medical Officer, Kim Jae B., reported receiving a new stock option award in common stock. On February 6, 2026, a stock option covering 125,000 shares was granted with an exercise price of $25.41 per share.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, contingent on Kim’s continuous service with Septerna. After this grant, Kim holds 125,000 stock options directly.
Septerna, Inc. reported that President and COO Elizabeth Bhatt received a stock option grant on February 6, 2026. The option covers 155,000 shares of common stock at an exercise price of $25.41 per share and is held directly.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as Bhatt continues to provide service to Septerna.
Septerna, Inc. reported that President and COO Elizabeth Bhatt received a stock option grant on February 6, 2026. The option covers 155,000 shares of common stock at an exercise price of $25.41 per share and is held directly.
According to the vesting terms, 2/48 of the option will vest and become exercisable on March 1, 2026. The remaining shares will vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, as long as Bhatt continues to provide service to Septerna.
Septerna, Inc. reported a stock option grant to its Chief Executive Officer and director, Jeffrey Finer. On February 6, 2026, he was awarded a stock option to purchase 400,000 shares of Septerna common stock at an exercise price of $25.41 per share.
The option expires on February 5, 2036. According to the vesting schedule, 2/48 of the shares will vest and become exercisable on March 1, 2026, and the remaining shares will vest in 46 substantially equal monthly installments, subject to his continuous service with the company.
Septerna, Inc. reported a stock option grant to its Chief Executive Officer and director, Jeffrey Finer. On February 6, 2026, he was awarded a stock option to purchase 400,000 shares of Septerna common stock at an exercise price of $25.41 per share.
The option expires on February 5, 2036. According to the vesting schedule, 2/48 of the shares will vest and become exercisable on March 1, 2026, and the remaining shares will vest in 46 substantially equal monthly installments, subject to his continuous service with the company.
Septerna, Inc. reported that its Chief Legal Officer, Mark Andrew Wilson, received a grant of stock options on February 6, 2026. The grant covers 165,000 stock options, each allowing the purchase of one share of Septerna common stock at an exercise price of $25.41 per share.
According to the vesting terms, 25% of the shares underlying the option will vest on January 5, 2027, with the remaining 75% vesting in thirty-six substantially equal monthly installments after that date, contingent on his continued service with the company.
Septerna, Inc. reported that its Chief Legal Officer, Mark Andrew Wilson, received a grant of stock options on February 6, 2026. The grant covers 165,000 stock options, each allowing the purchase of one share of Septerna common stock at an exercise price of $25.41 per share.
According to the vesting terms, 25% of the shares underlying the option will vest on January 5, 2027, with the remaining 75% vesting in thirty-six substantially equal monthly installments after that date, contingent on his continued service with the company.
Septerna, Inc. filed an initial insider ownership report for its Chief Legal Officer, Mark Andrew Wilson. This Form 3 filing identifies Wilson as an officer of the company but states that he does not beneficially own any Septerna securities at the time of the report. The document also includes a power of attorney authorizing the filing on his behalf.